Salud financiera de hoja de balance de Sanofi

Salud financiera controles de criterios 6/6

Sanofi tiene un patrimonio de accionistas total de €74.4B y una deuda total de €18.4B, lo que sitúa su ratio deuda-patrimonio en 24.8%. Sus activos y pasivos totales son €126.5B y €52.1B respectivamente. El BAIT de Sanofi es de €8.8B, por lo que su ratio de cobertura de intereses es de 115.9. Tiene efectivo e inversiones a corto plazo que ascienden a €8.7B.

Información clave

24.8%

Ratio deuda-patrimonio

€18.42b

Deuda

Ratio de cobertura de intereses	115.9x
Efectivo	€8.71b
Patrimonio	€74.35b
Total pasivo	€52.11b
Activos totales	€126.46b

Actualizaciones recientes sobre salud financiera

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Apr 13

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Nov 19

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (€30.7B) de SAN superan a sus pasivos a corto plazo (€24.2B).

Pasivo a largo plazo: Los activos a corto plazo de SAN (€30.7B) superan a sus pasivos a largo plazo (€27.9B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (13.1%) de SAN se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de SAN ha pasado de 41.7% a 22% en los últimos 5 años.

Cobertura de la deuda: La deuda de SAN está bien cubierta por el flujo de caja operativo (62.6%).

Cobertura de intereses: Los pagos de intereses de la deuda de SAN están bien cubiertos por el BAIT (115.9x cobertura).

Salud financiera de hoja de balance de Sanofi

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Recent updates

Upcoming dividend of €3.76 per share

Sanofi Announces Board and Committee Appointments

Sanofi Announces Board and Committee Appointments

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 17%

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Full year 2023 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Consensus EPS estimates increase by 13%

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

New minor risk - Profit margin trend

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sanofi Announces CFO Changes, Effective April 1, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Sanofi to Report Q3, 2024 Results on Oct 25, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Sanofi's (EPA:SAN) Price Is Right But Growth Is Lacking

Sanofi to Report Q4, 2023 Results on Feb 01, 2024

Sanofi Announces Dupixent Significantly Reduced (34%) Exacerbations, Confirming Positive Published Results from the Landmark Phase 3 Boreas Trial

Sanofi to Report Q2, 2024 Results on Jul 25, 2024

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Price target decreased by 8.3% to €106

Third quarter 2023 earnings: EPS misses analyst expectations

Sanofi Reiterates Earnings Guidance for the Year 2023

Investor sentiment deteriorates as stock falls 18%

Sanofi Announces Positive Results from a Phase 3 Trial Demonstrated the Efficacy and Safety Profile of Dupixent (Dupilumab) for Up to One Year (52 Weeks) in Children Aged 1 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Sanofi Delivers First Medicines from Global Health Unit's Impact Brand Portfolio

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Atnahs Pharma UK Limited acquired Global Central Nervous System Portfolio from Sanofi (ENXTPA:SAN).

Sanofi Announces Changes to Its Executive Committee

Sanofi, Annual General Meeting, Apr 30, 2024

Sanofi Announce that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera